Researchers sought to determine if discontinuation of TKI therapy was safe for pediatric patients with CML ..read more

Illness uncertainty and self-perceived burden were identified as factors that may be associated with reduced quality of life (QOL) for patients with chronic myeloid leukemia (CML). These study results were reported in the Journal of Clinical Nursing. This descriptive study followed a cross-sectional design. Patients included in the study had been recruited from 4 university hospitals within Chongqing City, China, and were willing to participate. Participants were adults with chronic-phase CML who had been receiving treatment with tyrosine kinase inhibitors for 3 or more months. Patients comple ..read more

Tyrosine kinase inhibitors (TKIs) have demonstrated long-term survival benefits for patients with chronic myeloid leukemia (CML). But the risks associated with use of these agents, notably long-term TKI-associated vascular adverse events (VAEs), are concerning. Therefore, a team of researchers conducted a retrospective cohort study to determine the incidence of VAEs in patients with CML treated with imatinib, nilotinib, or dasatinib. The researchers pulled data from the Taiwan Cancer Registry Database and the National Health Insurance Research Database, including a total of 1111 patients with ..read more

Clinical management of patients with chronic myelogenous leukemia (CML) who are receiving tyrosine kinase inhibitors (TKIs) may be improved by assessing ankle-brachial blood pressure index (ABI) and cardiac ankle vascular index (CAVI). These findings were published in the International Journal of Hematology. TKIs have improved clinical outcomes for patients with CML; however, long-term TKI exposure has been associated with cardiovascular adverse events (CAEs). This study sought to assess whether evaluating patients for additional cardiovascular features may improve risk stratification. Patient ..read more

Patients with chronic myeloid leukemia (CML) who are treated with certain tyrosine kinase inhibitors (TKIs) may have a greater risk for adverse cardiovascular events. But healthcare providers do not have a standardized method for assigning a cardiovascular risk stratification to those patients. A team of Australian researchers  conducted a retrospective study of patients receiving TKI therapy to analyze the possible utility of incorporating baseline risk factors and coronary artery calcium scoring (CACS) into an assessment. Their findings were published in the Internal Medicine Journal. C ..read more

A systematic review found that evidence about adherence to tyrosine kinase inhibitors (TKIs) among patients with chronic myeloid leukemia (CML) has largely overlooked the patient perspective. These findings were published in the American Journal of Clinical Oncology. Researchers from the University of South Carolina searched publication databases for studies on adherence to TKI treatment of CML. As nonadherence remains a significant problem and is associated with increased mortality, the reviewers wanted to assess best practices for maintaining adherence. A total of 14 articles were included i ..read more

The use of tyrosine kinase inhibitors (TKIs) has dramatically changed how chronic myeloid leukemia (CML) is managed and improved survival rates. That’s especially true for second- and third-generation TKIs. However, that improvement comes with another type of cost: a heavier toxicity profile, including adverse cardiovascular events (CVAEs). In this report, a team of researchers in Italy reviewed CVAE risks associated with the use of TKIs in patients with CML. Their report, published in Frontiers in Physiology, discussed the cardiac and vascular toxicity of 5 ABL-inhibiting TKIs. Imatinib This ..read more

Patients with chronic myeloid leukemia (CML) who are receiving tyrosine kinase inhibitor (TKI) therapy should be evaluated for pulmonary hypertension (PH), according to results of a retrospective analysis published in Medicine. The TKI dasatinib has been associated with PH, but published data about other TKIs are scarce. To assess for a possible link between PH and all TKIs, researchers from Chungnam National University College of Medicine in South Korea reviewed their institutional records from 2003 to 2020 and identified 112 patients with CML who received TKI therapy and underwent transthora ..read more

Many patients with cancer are prescribed oral chemotherapy agents. A protocol for a study, published in Research in Nursing and Health, is seeking to determine the real-world adherence and clinical success of these therapies. Researchers from Emory University have proposed an observational study that will assess monthly adherence to tyrosine kinase inhibitors (TKIs) among patients with chronic myeloid leukemia (CML) over the course of 12 months. The follow-up duration was chosen, as it is significant CML and allows for more robust prediction of long-term clinical outcomes. The investigators wi ..read more

Drug-induced hepatotoxicity is a concern because half of the currently available oral drugs are associated with hepatotoxicity, including some used to treat chronic myeloid leukemia (CML). A team of researchers in China sought to determine the relative hepatotoxicology associated with new-generation BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (BCR-ABL TKIs) used to treat patients with CML. To better understand how these drugs affect liver function in patients with CML, the researchers analyzed data from 9 clinical trials including a total of 3475 patients published between 2000 and 2 ..read more